Apollomics, Inc. (APLM)
NASDAQ: APLM · Real-Time Price · USD
14.30
+0.24 (1.71%)
May 29, 2026, 1:54 PM EDT - Market open
Apollomics Revenue
In the year 2025, Apollomics had annual revenue of $8.84M with 776.31% growth. Apollomics had revenue of $342.00K in the half year ending December 31, 2025, with 2.70% growth.
Revenue (ttm)
$8.84M
Revenue Growth
+776.31%
P/S Ratio
3.49
Revenue / Employee
$631,571
Employees
14
Market Cap
31.40M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 8.84M | 7.83M | 776.31% |
| Dec 31, 2024 | 1.01M | 545.00K | 117.46% |
| Dec 31, 2023 | 464.00K | -552.00K | -54.33% |
| Dec 31, 2022 | 1.02M | 1.01M | 50,700.00% |
| Dec 31, 2021 | 2.00K | -1.84M | -99.89% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Barinthus Biotherapeutics | 14.97M |
| IGC Pharma | 1.11M |
| Lisata Therapeutics | 170.00K |
| Senti Biosciences Holdings | 38.00K |
| Neuphoria Therapeutics | -13.27K |
APLM News
- 14 days ago - Apollomics Registration statement: Registration filing - Filings
- 4 weeks ago - Apollomics Reports Full Year 2025 Financial Results and Provides Clinical Updates and Business Progress - GlobeNewsWire
- 4 weeks ago - Apollomics Annual report: Q4 2025 - Filings
- 4 weeks ago - Apollomics Earnings release: Q4 2025 - Filings
- 2 months ago - Apollomics Inc. Announces $2.0 Million Bridge Financing - GlobeNewsWire
- 2 months ago - Apollomics files to sell 279,775 Class A Ordinary shares for holders - TheFly
- 2 months ago - Apollomics Registration statement: Registration Filing - Filings
- 5 months ago - Apollomics Inc trading resumes - TheFly